Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 20,000 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $210.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the senior vice president now directly owns 86,725 shares in the company, valued at $18,212,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mostafa Ronaghi also recently made the following trade(s):

  • On Wednesday, August 2nd, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The stock was sold at an average price of $195.00, for a total transaction of $1,950,000.00.

Illumina, Inc. (NASDAQ:ILMN) traded down 0.25% during mid-day trading on Friday, reaching $209.68. 437,617 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $191.38 and its 200 day moving average is $178.42. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $211.27. The stock has a market capitalization of $30.61 billion, a PE ratio of 42.07 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. The company had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.86 earnings per share. Analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Mostafa Ronaghi Sells 20,000 Shares of Illumina, Inc. (ILMN) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/08/mostafa-ronaghi-sells-20000-shares-of-illumina-inc-ilmn-stock.html.

A number of brokerages have weighed in on ILMN. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, August 9th. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Cowen and Company reiterated an “outperform” rating and issued a $200.00 price objective on shares of Illumina in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $177.01.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. First Citizens Bank & Trust Co. raised its position in Illumina by 0.4% during the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after acquiring an additional 12 shares during the last quarter. Patten Group Inc. raised its position in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after acquiring an additional 25 shares during the last quarter. Puzo Michael J raised its position in Illumina by 0.4% during the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after acquiring an additional 25 shares during the last quarter. Flagship Harbor Advisors LLC raised its position in shares of Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after buying an additional 35 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its position in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after buying an additional 38 shares during the last quarter. Institutional investors own 93.34% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.